Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

Advanced Biliary Tract Cancer Clinical Trial

Official title:

Envofolimab and Lenvatinib in Combination With Gemcitabine Plus Cisplatin for Patients With Advanced Biliary Tract Cancer as First-Line Treatment: A Single-arm, Open-label, Phase II Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05410197
• Other study ID #: BTC2022
• Status: Recruiting
• Phase: Phase 2
• Start date: October 10, 2022
• Est. completion date: August 1, 2025

Study information

• Verified date: October 2022
• Source: Sun Yat-sen University
• Contact: Ming Kuang, PhD
• Phone: 008687755766
• Email: kuangm[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2, single-arm, open label study. The purpose is to investigate both the efficacy and safety of Envofolimab and Lenvatinib in combination with Gemcitabine plus Cisplatin for treatment of advanced biliary tract cancer as first-line treatment.

Description:

The trial will recruit 43 patients. At the first step, 10 patients will be recruited. Only when at least 4 patients achieve objective response will the trial enter the second step and continue to recruit other patients. After being enrolled, all patients giving written informed consent will receive treatment until progression of disease, unacceptable toxicity or death. The tumor response evaluation will be conducted on a regular basis until progression of disease. Long-term survival follow up will be conducted as well.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 43
• Est. completion date: August 1, 2025
• Est. primary completion date: August 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent obtained from the patient prior to treatment.

2. Age > 18 years at the time of study entry.

3. Pathologically confirmed advanced biliary tract cancer, not having received systemic therapy.

4. Measurable or evaluable lesions according to RECIST v1.1 criteria.

5. Eastern Cooperative Oncology Group (ECOG) performance status = 1.

6. Life expectancy = 12 weeks.

7. Adequate hematologic (absolute neutrophil count = 1,500/µL, platelets count = 100,000/µL, hemoglobin = 9.0 g/dL), renal (serum creatinine = 1.5 × upper limit of normal (ULN) or creatinine clearance = 50 mL/min (Cockcroft-Gault), urinary protein < 2+ or = 1g/24h) and hepatic function (total serum bilirubin = 1.5 ×ULN, serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) = 2.5 × ULN).

8. Normal coagulation function (INR = 1.5 × ULN, APTT = 1.5 × ULN, PT = 1.5 × ULN), without active bleeding or thrombotic diseases.

9. Willingness and ability to comply with the protocol.

Exclusion Criteria:

1. Diagnosis of any second malignancy, except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix uteri.

2. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

3. Previous treatment with Chinese herbal medicine or immunomodulators within 2 weeks, or radiotherapy treatment within 4 weeks prior to the first dose of administration.

4. Abnormal thyroid function.

5. Uncontrolled hypertension.

6. Uncontrolled cardiac disease, including but not limited to heart failure (NYHA class II-IV), unstable angina pectoris, myocardial infarction within 1 year or cardiac arrhythmia.

7. Active or prior documented autoimmune or inflammatory disorders.

8. Any immunosuppressants or systemic steroid therapy (> 10 mg daily dose of prednisone or equivalent) within 2 weeks prior to enrollment.

9. Central nervous system metastases.

10. Active infection or unknown fever(>38.5?) prior to the first dose of administration, except for cancerous fever.

11. History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-associated pneumonia or severely impaired lung function.

12. Inherited or acquired immunodeficiency disease, including but not limited to infection of HIV or active hepatitis (HBV DNA = 1000 IU/ml or HCV RNA = 1000 IU/ml).

13. Live vaccine administration within 4 weeks prior to the first dose of administration or probably during the study.

14. History of psychotropic substance abuse, alcohol abuse, or drug use.

15. Pregnancy or lactation

16. Exclusion from the study by the judgement of investigator, due to some factors that may lead to the forced termination of the study.

Related Conditions & MeSH terms

• Advanced Biliary Tract Cancer
• Biliary Tract Neoplasms

Intervention

Drug:
• Envofolimab
400mg by subcutaneous injection every 3 weeks
• Lenvatinib
8 mg orally once a day
• Gemcitabine
1000mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
• Cisplatin
25mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	ORR is defined as the percentage of patients who have achieved complete response (CR) or partial response (PR), as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.	Up to 2 years
Secondary	Overall Survival (OS)	OS is defined as the time from first treatment to death, regardless of disease recurrence.	Up to 2 years
Secondary	Progression-Free Survival (PFS)	PFS is defined as the time from the first dose of administration to progression or death.	Up to 2 years
Secondary	Disease control rate (DCR)	DCR is defined as the percentage of patients who have achieved CR, PR or stable disease(SD), as measured by RECIST 1.1 criteria.	Up to 2 years
Secondary	Incidence of Adverse Events (AE)	The percentage of patients who suffer grade 3 or worse adverse events from the first dose of administration to last follow-up, assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.	Up to 2 years